Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02314169 · OUTCOME

Progression-free Survival (Part A)

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer · Source last updated 2026-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From initiation of treatment with nivolumab until the time of disease progression, assessed up to 2 years

What was measured

From initiation of treatment with nivolumab until the time of disease progression, time measured in months. Kaplan-Meier analysis performed to estimate the median progression-free survival with a 95% confidence interval.

Groups in this outcome

Part A: Nivolumab

This outcome measure is assessed from patients enrolled onto Part A of this study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A: Nivolumab37

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Part A: Nivolumab4.1Not reported3.07.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.0
        upper Limit
        7.9
        value
        4.1
denoms
  1. counts
    1. group Id
      OG000
      value
      37
    units
    Participants
description
From initiation of treatment with nivolumab until the time of disease progression, time measured in months. Kaplan-Meier analysis performed to estimate the median progression-free survival with a 95% confidence interval.
dispersion Type
95% Confidence Interval
groups
  1. description
    This outcome measure is assessed from patients enrolled onto Part A of this study.
    id
    OG000
    title
    Part A: Nivolumab
param Type
MEDIAN
reporting Status
POSTED
time Frame
From initiation of treatment with nivolumab until the time of disease progression, assessed up to 2 years
title
Progression-free Survival (Part A)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice